March 2023:
Isifinyezo esifushane:
Inhloso yalolu cwaningo lomtholampilo ukuthola ukuthi i-anti-MESO antigen receptor yini Ukwelashwa kwe-CAR T-cell can isetshenziselwe ukwelapha ei-pithelial ovarian cancer ebuyile noma eyekile ukuphendula kwezinye izindlela zokwelapha.
Imininingwane eningiliziwe:
Izinjongo Eziyinhloko
Ukunquma ukuthi kungenzeka yini kanye nokuphepha kwamaseli e-anti-MESO CAR-T ekwelapheni iziguli ezinomdlavuza we-ovarian we-MESO-positive.
Izinjongo Zesibili
Ukuhlola ukusebenza kahle kwamaseli e-anti-MESO CAR-T ezigulini ezinomdlavuza we-ovarian.
Ukunquma ukuguquguquka kwe-vivo nokuphikelela kwamaseli e-anti-MESO CAR-T.
Isakhiwo sokufunda
Uhlobo lokufunda : Ukungenelela (Isivivinyo Somtholampilo)
Ukubhaliswa Okulinganiselwe : Abahlanganyeli abangu-20
Isabelo: N/A
Imodeli Yokungenela: Isabelo Seqembu Elilodwa
Ukufihla: Akukho (Vula ilebula)
Inhloso Eyinhloko: Ukwelashwa
Isihloko Esisemthethweni: Ukuphepha kanye nokusebenza ngempumelelo kwe-MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Idethi elinganiselwe yokuqala yokufunda : Ephreli 20, 2019
Idethi Yokuqeda Okuyisisekelo Elinganiselwe : Ephreli 20, 2022
Idethi Elinganiselwe Yokuqeda Isifundo : Ephreli 20, 2023
Imigomo
Imigomo Yokufaka:
Iminyaka engu-18 kuya kwengama-70 ubudala, owesifazane; Ukusinda okulindelekile> amasonto ayi-12; Isimo sokusebenza komtholampilo sesikolo se-ECOG 0–2; Iziguli ezike zelashwa ngaphambilini ngomugqa wesibili noma imigqa eminingi yokwelashwa okujwayelekile azisebenzi (Akukho ukuxolelwa noma ukuphindeka ngemva kokuxolelwa); Okungenani i-foci yesimila esisodwa esilinganisekayo ngokwezinga le-RECIST 1.1; I-Positive Mesothelin expression in tumor tissue; I-Creatinine ≤ 1.5×ULN; I-ALT ne-AST ≤ 3×ULN; Isamba se-bilirubin ≤ 2×ULN; I-Hemoglobin≥90g/L; Ukubala okuphelele kwama-neutrophils≥1000uL; Ukubala okuphelele kwama-lymphocyte>0.7×10^9/L; Ukubalwa kwama-Platelets≥75000/uL; Ukufinyelela kwe-venous okudingekayo ukuze kuqoqwe kungasungulwa ngaphandle kokuphikisana nokuqoqwa kwe-leukocyte. Ngiyakwazi ukuqonda nokusayina idokhumenti yemvume enolwazi.
Imigomo Yokukhishwa:
Ihambisana nezinye izimila ezimbi ezingalawuleki; I-hepatitis B esebenzayo, i-hepatitis C, i-syphilis, ukutheleleka nge-HIV; Izifo ezinzima zenhliziyo noma zokuphefumula; Noma yiziphi ezinye izifo zingathinta umphumela walolu cwaningo. Noma yiziphi izindaba ezingase zibe nomthelela ekuphepheni kwezihloko noma umphumela walolu cwaningo Abesifazane abakhulelwe noma abancelisa, noma iziguli ezihlela ukukhulelwa ngesikhathi noma ngemva kokwelashwa; Kukhona izifo ezisebenzayo noma ezingalawuleki (ngaphandle kwezifo ezilula ze-urinary tract noma izifo eziphezulu zokuphefumula) ezidinga ukwelashwa kwe-systemic izinsuku ezingu-14 noma izinsuku ezingu-14 ngaphambi kokunikezwa; Iziguli ezibhekwa abacwaningi njengezingafanele lokhu kuhlolwa; Uthole ukwelashwa kwe-CAR-T noma ezinye izindlela zokwelapha zofuzo ngaphambi kokunikezwa; Isifo esiphethwe yisihloko sithinta ukuqonda kwemvume enolwazi noma ukuhambisana nephrothokholi yocwaningo.
Bheka uhlu lwezibhedlela ezikwenzayo I-CAR T-Cell therapy e-China.
